Calendario›TCRX›Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes
Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes
Ensayo de TScan Therapeutics, Inc. en Identify the Viral Epitopes of Memory CD8 T Cells From Individuals That Have Recovered From SARS-CoV-2 Infection · Determine Which SARS-CoV-2 Proteins Are Frequently Recognized by T Cells in Patients With Varying HLA Types (del registro, en inglés).
- Fase
- no aplica
- Estado
- Completado
- Participantes
- 80
- Centros
- 2
- Fin del objetivo primario
- abr 2021
Qué significa cada fase y cada estado.
Estudio observacional. Comenzó en abr 2020.
Qué mide
Identify the viral epitopes of memory CD8+ T cells from individuals that have recovered from SARS-CoV-2 infection. (JUL2020) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThe COVID-19 pandemic is a global emergency threatening to take millions of lives in the United States and around the world. There is no current vaccine strategy against COVID-19 infection caused by a novel coronavirus named SARS-CoV-2. Studies with a related coronavirus called SARS-CoV-1 that caused the SARS outbreak in 2003 indicated that memory CD8+ T cells recognizing viral epitopes persisted for more than 6 years post infection while neutralizing antibodies and memory B cells were short-lived and were undetectable after a short period of time (Tang et al., 2011; Peng et al., 2006; Channappanavar et al., 2014). Thus, including viral epitopes that are recognized by memory CD8+ T cells is imperative for vaccines that can provide long-term immunity against SARS-CoV-2. In this study, blood samples from COVID-19 patients who have recovered from the infection will be used to identify the viral epitopes recognized by their memory CD8+ T cells. This will be accomplished using a genome-wide, high-throughput screening technology developed at Harvard Medical School (Kula et al., 2019) and licensed by the study sponsor, TScan Therapeutics. A 24,000-member library that tiles across all \~100 viral isolates of SARS-CoV-2 that have been sequenced so far has already been synthesized at TScan. Blood samples from convalescent patients are urgently needed to identify T cell receptors and immunogenic viral epitopes on SARS-CoV-2. It is the hope that these data will inform development of a vaccine with the potential for long-lasting protection against SARS-CoV-2.
Más ensayos de TCRX
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors | no aplica | En marcha, sin reclutar | ene 2026 (prevista, ya pasada: sin actualizar en el registro) |
| SOC + TSC-101 | Fase 1 | Reclutando pacientes | jun 2026 (real) |
| TSC-204-A0201 | Fase 1 | En marcha, sin reclutar | dic 2026 (prevista) |
| TSC-101 · ALLOHA-2 | Fase 3 | Reclutando pacientes | jun 2029 (prevista) |
| LTFU | no aplica | Reclutando pacientes | sep 2040 (prevista) |
| A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease | no aplica | Completado | sep 2026 (real) |
Todos los de TCRX, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT04397900), actualizada en abr 2021.